Calcium Stimulated Calcitonin Measurement: A Procedural Proposal

 

 Buy Article Permissions and Reprints

Abstract

Human calcitonin (hCT) is a tumor marker essential to the diagnosis and follow-up of medullary thyroid cancer (MTC). Current consensus recommends hCT measurement when initially evaluating thyroid nodules; if slightly elevated, a confirmatory stimulated calcitonin test is commonly performed, usually using pentagastrin. In recent years the supply of pentagastrin was not guaranteed with long periods of unavailability; the outlook for future availability is unknown. Therefore it is desirable for many institutions to establish a procedure for calcitonin stimulation using a stimulant with a secure supply; stimulation of calcitonin using calcium represents the easiest alternative.

Several schemes and dosages have been used in the past for calcium stimulated calcitonin measurement. In this paper we propose a procedure for calcium stimulated calcitonin measurement based on our experiences. Furthermore we will briefly point out the limitations of this method with regard to available data in literature.

• References

• 1 Dietlein M, Dressler J, Grünwald F et al. Leitlinie zur Schilddrüsendiagnostik. Deutsche Gesellschaft für Nuklearmedizin 2003;
  PubMedGoogle Scholar
• 2 Karges W, Dralle H, Raue F et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112: 52-58
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Owyang C, Heath III H, Sizemore GW et al. Comparison of the effects of pentagastrin and meal-stimulated gastrin on plasma calcitonin in normal man. Am J Dig Dis 1978; 23: 1084-1088
  CrossrefPubMedGoogle Scholar
• 4 Sizemore GW, Go VL. Stimulation tests for diagnosis of medullary thyroid carcinoma. Mayo Clin Proc 1975; 50: 53-56
  PubMedGoogle Scholar
• 5 Hennessy JF, Wells Jr SA, Ontjes DA et al. A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1974; 39: 487-495
  CrossrefPubMedGoogle Scholar
• 6 Hennessy JF, Gray TK, Cooper CW et al. Stimulation of thyrocalcitonin secretion by pentagastrin and calcium in 2 patients with medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1973; 36: 200-203
  CrossrefPubMedGoogle Scholar
• 7 Wells Jr SA, Cooper CW, Ontjes DA. Stimulation of thyrocalcitonin secretion by ethanol in patients with medullary thyroid carcinoma – an effect apparently not mediated by gastrin. Metabolism 1975; 24: 1215-1219
  CrossrefPubMedGoogle Scholar
• 8 Doyle P, Duren C, Nerlich K et al. Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab 2009; 94: 2970-2974
  CrossrefPubMedGoogle Scholar
• 9 Colombo C, Verga U, Mian C et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J Clin Endocrinol Metab 2012; 97: 905-913
  CrossrefPubMedGoogle Scholar
• 10 Kratzsch J, Petzold A, Raue F et al. Comparison of basal and stimulated calcitonin and procalcitonin using different commercially available assays in patients with and without medullary thyroid cancer. Clin Chem 2010; in Press
  PubMedGoogle Scholar
• 11 Colombo C, Verga U, Perrino M et al. High-dose calcium and pentagastrin tests in patients with cured or persistent medullary thyroid cancer and in controls: comparison of the efficacy and the tolerance. Abstract, ITC 2010 2010; 2040.
  PubMedGoogle Scholar
• 12 Machens A, Hoffmann F, Sekulla C et al. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocr Relat Cancer 2009; 16: 1291-1298
  CrossrefPubMedGoogle Scholar